KMT2A and acute promyelocytic leukemia: Type II mutation involves disrupting transcription factors or transcriptional coactivators, such as acute myeloid leukemia-1 transcription factor/eight-twenty-one corepressor (AML1/ETO), mixed-lineage leukemia/ALL1-fused gene from chromosome 9 protein (MLL/AF9), and promyelocytic leukemia/retinoic acid receptor α (PML/RARα) fusion gene.